Category Archives: pricing

AMCP Talk Pricing of Specialty Pharma Spurred by Sovaldi

Starting off this week’s Academy of Managed Care Pharmacy (AMCP) meeting in Boston, experts including patient access advocates, pharma and payer representatives came together for this year’s symposium entitled “Specialty Pharmacy and Patient Care: Are We at a Tipping Point?”
Also posted in healthcare, Market Access | Tagged , , , , , , , | Leave a comment

Five Measures to Cope with the Side Effects of Health Reform

By Sydney Rubin. With more than 8 million Americans now signed up for health insurance through state health exchanges, The Affordable Care Act (ACA) has begun delivering benefits and new insurance protections to a large swath of Americans, many of whom had no health insurance before. People previously rejected by insurers due to pre-existing conditions […]
Also posted in Guest Blog, healthcare, Op-Ed, Regulatory | Tagged , , , | Leave a comment

UK Postpones Decision on Value-Based Assessment — Again

By Leela Barham. Value-based Pricing (VBP) was first discussed as far back as 2007 by the UK’s consumer authority, the now defunct Office of Fair Trading (OFT).  The general concept of VBP was to set almost provisional prices based on the expected value of new medicines using immature data, with provisions to ‘correct’ the price […]
Also posted in Europe, Global, Guest Blog, Op-Ed | Tagged , , , , , , | Leave a comment

PPRS Payments Now Worth £150m in the UK

By Leela Barham. A second payment has now been made under the UK’s Pharmaceutical Price Regulation Scheme (PPRS). Adding a further £76m to the £74m for the first quarter of 2014, the payments received by the Department of Health (DH) now total £150m (US$244m).  Payments are a new feature of the long-standing voluntary PPRS. The […]
Also posted in Europe, Guest Blog, Op-Ed, Regulatory | Tagged , , | Leave a comment

Managing High-Priced, US Biotech Rxs in Canada

As the “Saga of Sovaldi” continues to unfold in the U.S., and Congress, insurers, providers, and the U.S. Rx manufacturer, Gilead, hurl charges back and forth at each other, it’s pretty clear the situation will only continue to deteriorate. However, as you look north of the American border, it’s striking how Canadian healthcare entities are managing […]
Also posted in Op-Ed | Tagged , , , , | Leave a comment
  • Categories

  • Meta